|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 伴有或不伴有肝实质侵犯的卵巢癌周围性转移CT检出的敏感性与特异性研究显示文摘目的回顾性确定由不同经验水平的放射医生读片时,伴有或不伴肝实质侵犯(LPI)的卵巢癌病人肝周围性转移CT鉴别的敏感性与特异性。研究以剖腹探查分期及病理检查为参考标准。方法学院医学伦理委员会批准此项研究不必签署知情同意书,研究符合HIPAA要求。121例卵巢癌病人(年龄29~94岁,平均57.8岁)纳入本研究。2位放射医生(放射医生1:6个月专业经验;放射医生2:2年6个月专业经验)在不知道病人临床资料情况下,相互独立地回顾性记录CT显示是否有周围性转移, | O. Akin E. Sala C.S. Moskowitz N. Ishill R.A. Soslow D.S. Chi 唐光健(译) | 2008 | 国际医学放射学杂志2008，31，5： | 4 |
| 2 | Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer显示文摘 | C.H. Kim N.R. Abu-Rustum D.S. Chi G.J. Gardner M.M. Leitao J. Carter R.R. Barakat Y. Sonoda | 2012 | Gynecologic Oncology2012，，3： | 2 |
| 3 | Lower circulating irisin is associated with type 2 diabetes mellitus显示文摘 | Jian-Jun Liu Melvin D.S. Wong Wan Ching Toy Clara S.H. Tan Sylvia Liu Xiao Wei Ng Subramaniam Tavintharan Chee Fang Sum Su Chi Lim | 2013 | Journal of Diabetes and Its Complications2013，，4： | 1 |
| 4 | Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy显示文摘 | O. Zivanovic M.M. Leitao K.J. Park H. Zhao J.P. Diaz J. Konner K. Alektiar D.S. Chi N.R. Abu-Rustum C. Aghajanian | 2008 | Gynecologic Oncology2008，，3： | 1 |
| 5 | Lower circulating irisin is associated with type 2 diabetes mellitus显示文摘 | Jian-Jun Liu Melvin D.S. Wong Wan Ching Toy Clara S.H. Tan Sylvia Liu Xiao Wei Ng Subramaniam Tavintharan Chee Fang Sum Su Chi Lim | 2013 | Journal of Diabetes and Its Complications2013，，4： | 1 |
| 6 | 子宫内膜癌并卵巢癌患者呈现副肿瘤综合征时的乳糜泻 | Haddad L Amsterdam A D.S. Chi 张旸 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，10： | 0 |
| 7 | 卵巢上皮癌二探手术阳性患者预后因子的研究显示文摘Objective.: The objective of this study was to identify independent prognostic factors for survival in patients with epithelial ovarian cancer who had persistent disease identified at second look surgery. Methods.: We performed a retrospective chart review of all patients with epithelial ovarian cancer who had positive findings at second-look surgery between June 1991 and June 2002. All patients achieved a complete clinical remission after a prescribed course of primary therapy. Survival was determined from the time of second-look surgery until last follow-up or death. Results.: The study included a total of 262 patients, with a median age of 54 years(range, 22-80). Of the 262 patients, 166(63%) had died of disease. Records of initial(salvage) treatment after the positive second-look surgery were available for 243 patients. Therapies included the following: intraperitoneal(IP) cisplatin, 71(29%); IP cisplatin combined with a second drug, 53(22%); IP therapy other than cisplatin, 29(12%); intravenous(IV) chemotherapy, 50(21%); IP and IV therapy, 35(14%); and oral chemotherapy, 5(2%). Of the 13 potential prognostic factors analyzed, only 2 factors emerged that, when combined, were significant-residual disease after primary surgery and size of persistent disease found at second-look surgery. Patients with ≤1 cm residual disease after primary surgery and microscopic disease at second-look surgery had significantly improved survival. Conclusion.: In our analysis, the only prognostic factor for survival in patients with positive second-look procedures was a combination of residual disease after primary surgery and size of persistent disease identified at second-look surgery. No individual chemotherapy treatment imparted a survival advantage. Novel that therapeutic approaches are needed in this setting. | McCreath W.A. Eisenhauer E.L. Abu-Rustum N.R. D.S. Chi 朱磊 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员